List of Excipients in Branded Drug PAROXETINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis US LLC	PAROXETINE	paroxetine	0574-0279	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Padagis US LLC	PAROXETINE	paroxetine	0574-0279	FD&C RED NO. 3
Padagis US LLC	PAROXETINE	paroxetine	0574-0279	FD&C RED NO. 40
Padagis US LLC	PAROXETINE	paroxetine	0574-0279	FD&C YELLOW NO. 6

Generic Drugs Containing PAROXETINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	paroxetine hydrochloride hemihydrate	0378-7001	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Mylan Pharmaceuticals Inc	paroxetine hydrochloride hemihydrate	0378-7001	FD&C BLUE NO. 1
Mylan Pharmaceuticals Inc	paroxetine hydrochloride hemihydrate	0378-7001	HYDROXYPROPYL CELLULOSE
Mylan Pharmaceuticals Inc	paroxetine hydrochloride hemihydrate	0378-7001	HYPROMELLOSE

What are the Most Frequently-Used Excipients in PAROXETINE?

# Of NDCs	Excipient
3	ALUMINUM OXIDE
1	ANHYDROUS CITRIC ACID
72	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
82	ANHYDROUS LACTOSE

Paroxetine Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Paroxetine is a mature SSRI with limited value in the active pharmaceutical ingredient itself and greater commercial potential in formulation design. The strongest opportunities are low-dose products, modified-release systems, liquid and orally disintegrating dosage forms, menopausal vasomotor-symptom products, and differentiated generic versions with improved tolerability or administration.

Paroxetine hydrochloride immediate-release tablets are highly commoditized. Commercial differentiation depends on manufacturing cost, dissolution control, patient adherence, dose flexibility, and regulatory execution. Paroxetine controlled-release products and paroxetine mesylate capsules provide more defensible formulation targets, although the relevant patent and regulatory positions must be verified against the current FDA Orange Book and applicable international registers.

What formulations of paroxetine are commercially available?

The principal paroxetine products use three active-ingredient presentations: paroxetine hydrochloride immediate-release tablets, paroxetine hydrochloride controlled-release tablets, and paroxetine mesylate capsules.

Product type	Active ingredient	Typical strength	Primary indication or use	Excipient opportunity
Immediate-release tablet	Paroxetine hydrochloride hemihydrate	10-40 mg	Depression, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder, PTSD	Low-cost direct compression, scoreability, film coating, dose flexibility
Controlled-release tablet	Paroxetine hydrochloride	12.5-37.5 mg	Major depressive disorder, panic disorder, social anxiety disorder	Matrix or multiparticulate release control, reduced peak exposure, once-daily adherence
Low-dose capsule	Paroxetine mesylate	7.5 mg	Vasomotor symptoms associated with menopause	Low-dose content uniformity, capsule fill, lactose-free and excipient-minimized versions
Oral liquid	Usually paroxetine hydrochloride	Product-dependent	Pediatric or geriatric administration, where approved	Taste masking, preservative system, chemical stability, dosing accuracy
Orally disintegrating tablet	Paroxetine salt or adapted formulation	Product-dependent	Administration for patients with swallowing difficulty	Superdisintegrants, taste masking, low friability, moisture protection

Paxil immediate-release tablets and Paxil CR controlled-release tablets were approved in the United States before the market became dominated by generic paroxetine products. Brisdelle, a 7.5 mg paroxetine mesylate capsule, was approved by the FDA in 2013 for menopausal vasomotor symptoms.[1-3]

Which excipients are used in paroxetine products?

Paroxetine products generally use conventional pharmaceutical excipients rather than highly specialized delivery materials. The key excipient functions are compression, release control, coating, lubrication, capsule filling, taste masking, and stability.

Immediate-release tablets

Immediate-release paroxetine tablets commonly use combinations of:

• Dibasic calcium phosphate or another compressible diluent
• Hypromellose as a binder or film-forming polymer
• Povidone as a binder
• Magnesium stearate as a lubricant
• Colloidal silicon dioxide as a glidant
• Polyethylene glycol and polysorbate in film-coating systems
• Titanium dioxide and approved colorants for identification

The principal development issue is not achieving rapid disintegration. It is achieving robust content uniformity at low strengths while maintaining acceptable tablet hardness, friability, dissolution, and dose-unit consistency.

A formulation intended for a 10 mg or lower dose must control segregation between the active ingredient and the larger-volume diluent. Granulation, ordered mixing, co-processed excipients, or carrier-based premixes can reduce potency variability. Direct compression is commercially attractive where the active ingredient has suitable flow and compressibility, but roller compaction or wet granulation may be preferable when segregation or tablet weight variation is material.

Controlled-release tablets

Controlled-release paroxetine products require greater excipient specialization. Potential functional materials include:

• Hypromellose of controlled viscosity grades
• Polyethylene oxide
• Ethylcellulose
• Cellulose acetate
• Povidone or copovidone
• Insoluble or partially soluble matrix formers
• Film-coating polymers used for delayed or extended release
• Osmotic-system materials, where the design supports a suitable release profile

The reference Paxil CR product uses a controlled-release architecture intended to modify drug release and exposure relative to immediate-release paroxetine.[2] A generic developer must match the reference product’s dissolution profile across multiple pH conditions and demonstrate bioequivalence under the applicable FDA pathway.

The commercial value of controlled-release excipient design lies in release reproducibility. Polymer particle size, viscosity, hydration rate, compression force, tablet porosity, coating weight gain, and storage humidity can change the dissolution profile. A low-cost formulation that fails under accelerated stability or scale-up conditions has little commercial value.

How should excipient selection address paroxetine’s physicochemical properties?

Paroxetine is a basic, lipophilic SSRI marketed primarily as hydrochloride or mesylate salts. Excipient selection should account for salt form, pH-dependent solubility, low dose, hygroscopicity risk, and the need to control exposure during treatment initiation and dose changes.

Salt selection and microenvironmental pH

The hydrochloride and mesylate salts create different formulation options. Salt conversion may alter:

• Aqueous solubility
• Crystal form
• Hygroscopicity
• Particle morphology
• Dissolution rate
• Compatibility with acidic or alkaline excipients
• Capsule or tablet fill weight

Microenvironmental pH modifiers can improve dissolution or stabilize the salt, but they also create risks. Alkaline excipients may convert the salt toward free base, while acidic excipients may alter local solubility and release behavior. Compatibility screening should therefore assess assay, related substances, water content, polymorphic form, and dissolution after accelerated storage.

Low-dose content uniformity

The 7.5 mg Brisdelle strength and potential pediatric or titration products create a stronger need for blend uniformity than conventional 20 mg tablets. Commercially useful approaches include:

1. Pre-blending paroxetine with a controlled particle-size carrier.
2. Using geometric dilution before final blending.
3. Applying dry or wet granulation to immobilize the active ingredient.
4. Using co-processed excipients with predictable flow.
5. Selecting capsule-fill processes that limit segregation during transport and dosing.

The excipient system should be selected with the final manufacturing process in mind. A formulation that performs well in a laboratory V-blender may segregate in a high-throughput bin blender or capsule-filling line.

Moisture management

Moisture can affect tablet hardness, polymer hydration, salt stability, and dissolution. Hypromellose, povidone, starch derivatives, and some disintegrants can increase water uptake. Moisture-protective film coatings, high-barrier blister packaging, desiccants, and controlled drying may be more commercially effective than replacing a conventional excipient with a costly specialty material.

What commercial opportunities exist for paroxetine excipient innovation?

Low-cost immediate-release generics

The largest unit-volume opportunity remains the conventional tablet market. It is difficult to differentiate through excipients alone, but manufacturers can compete through:

• Fewer manufacturing steps
• Direct compression
• Lower-cost film coating
• Robust tablet scoring
• Fewer tablet strengths through flexible scoring
• Improved bottle stability
• Reduced tablet weight
• Alternative lactose-free or dye-free versions

The target customer is usually a pharmacy benefit manager, wholesaler, hospital, or generic distributor. Manufacturing cost and supply reliability matter more than premium pricing.

Controlled-release generic paroxetine

Controlled-release paroxetine offers more technical and regulatory value than immediate-release tablets. A successful product must manage:

• In vitro dissolution matching
• Fed and fasting bioequivalence
• Dose dumping risk
• Polymer variability
• Scale-up effects
• Stability of the release mechanism
• Manufacturing controls for coating or matrix formation

The preferred commercial strategy is often a platform technology that can be reused for other low-dose, highly potent or exposure-sensitive drugs. Paroxetine can function as a development asset for that platform, although the market size is smaller than for high-volume chronic therapies.

Pediatric liquid and geriatric dosage forms

Paroxetine has clinical use in populations that may have difficulty swallowing tablets, but pediatric use is indication-specific and requires appropriate regulatory support. A liquid formulation could offer dose titration and administration flexibility. The central technical problems are taste, chemical stability, preservative effectiveness, dosing-device accuracy, and avoidance of alcohol or high levels of cosolvent.

Potential excipient systems include:

• Syrup or sugar-free polyol bases
• Suspending agents
• Buffer systems
• Chelating agents
• Preservatives
• Flavor systems
• Ion-exchange resins or polymeric taste-masking materials

Taste masking is commercially important because paroxetine’s pharmacologic activity and bitterness can reduce adherence if the formulation is exposed in the mouth. A suspension that requires vigorous shaking or produces dose variability has limited market appeal.

Orally disintegrating tablets

An orally disintegrating paroxetine product could target patients with dysphagia, psychiatric treatment settings, and adherence-sensitive populations. The formulation must balance rapid disintegration with acceptable mouthfeel and low friability.

Useful excipients may include crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, mannitol, and taste-masking polymers. The active ingredient should not be released so rapidly that the product creates an unacceptable bitterness burden or clinically undesirable peak exposure.

Menopause-focused low-dose products

The 7.5 mg paroxetine mesylate product creates a distinct commercial segment. A differentiated product could compete through:

• Smaller capsule size
• Lactose-free formulation
• Vegetarian capsule shell
• Unit-dose packaging
• Improved heat and humidity stability
• Low-cost generic manufacturing
• Alternative tablet or orally disintegrating presentation

This segment is commercially distinct from antidepressant treatment because the dose, patient population, labeling, and payer dynamics differ. A product positioned for vasomotor symptoms should avoid unnecessary excipient complexity and preserve low-dose content uniformity.

What regulatory issues affect paroxetine excipient strategy?

The FDA inactive ingredient database is the starting point for determining whether a proposed excipient, route, dosage form, and maximum daily exposure have precedent.[4] A formulation using excipients outside established precedent may require additional justification, safety data, or a different regulatory pathway.

ANDA considerations

For an immediate-release generic, the excipient strategy should support pharmaceutical equivalence and bioequivalence. Differences from the reference product may be acceptable if they do not affect safety, efficacy, performance, or labeling requirements.

For controlled-release paroxetine, the development burden is higher. The sponsor must establish equivalence in release behavior and systemic exposure. Excipient changes that alter gastrointestinal transit, polymer hydration, or release kinetics can create bioequivalence risk even when the tablet contains the same strength.

505(b)(2) opportunities

A 505(b)(2) application may be commercially relevant for:

• A new dosage form
• A new route of administration
• A low-dose formulation for a different indication
• An oral liquid
• An orally disintegrating product
• A modified-release product using a new delivery technology

The pathway does not eliminate the need for clinical, safety, or bioequivalence evidence. Its value depends on whether the formulation creates a clinically meaningful product difference and whether the reference product and relevant exclusivities support reliance on existing data.

Excipient safety

Excipient selection must comply with FDA requirements, compendial standards where applicable, and global restrictions. Particular attention is required for:

• Preservatives in pediatric and chronic-use liquids
• Polyethylene glycol and propylene glycol exposure
• Colorants
• Lactose in patients with intolerance
• Gelatin capsule materials
• Titanium dioxide restrictions in certain jurisdictions
• Nitrosamine risk from excipient impurities or manufacturing conditions

ICH Q8, Q9, and Q10 principles support a quality-by-design approach in which excipient variability is linked to critical quality attributes such as dissolution, content uniformity, impurities, and stability.[5]

What patent and exclusivity issues affect paroxetine formulation products?

Paroxetine’s active-ingredient exclusivity is mature, so commercial risk is concentrated in formulation, method-of-use, manufacturing, and regulatory protections.

Orange Book and Paragraph IV risk

Immediate-release paroxetine tablets generally face a mature generic market. Relevant risks include:

• Paragraph IV challenges to listed formulation or method patents
• Labeling carve-outs for protected indications
• Patent certifications for controlled-release products
• ANDA litigation involving release technology
• Pediatric exclusivity or other regulatory exclusivity if applicable to a particular product
• Product-specific listing changes in the FDA Orange Book

A current Orange Book review is necessary for product-specific patent numbers, expiration dates, and litigation status because listings and litigation outcomes change over time.[6]

Formulation patentability

A potentially defensible formulation patent would need more than a routine substitution of one conventional excipient for another. Stronger claim themes include:

• A defined polymer ratio that produces a distinctive release profile
• A multiparticulate system with a specified dissolution window
• A stable low-dose formulation with demonstrated content uniformity
• A taste-masked liquid with defined stability and sensory performance
• A manufacturing process that reduces impurity formation
• A formulation that avoids a known incompatibility or improves storage stability

Patent strength depends on claim breadth, technical effect, reproducibility, prior art, and the ability to prove infringement from commercial-product testing.

Settlement and licensing

Paroxetine has a history of generic competition and formulation disputes in the broader SSRI market. Any current settlement, license, authorized-generic arrangement, or supply agreement should be evaluated through FDA filings, SEC disclosures, court dockets, and transaction documents. No single excipient supplier is structurally required for conventional paroxetine tablets, which limits the licensing value of ordinary diluents and lubricants.

Higher-value licensing opportunities may involve:

• Controlled-release polymer platforms
• Taste-masking technology
• Co-processed low-dose carriers
• Continuous manufacturing
• High-barrier packaging
• Specialty capsule systems

How does paroxetine compare with competing SSRIs?

Drug	Common formulation opportunity	Excipient complexity	Commercial differentiation
Paroxetine	Immediate-release, controlled-release, low-dose mesylate capsule, liquid, ODT	Moderate to high for CR and low-dose products	Release control, tolerability, low-dose menopausal product
Sertraline	Tablets, oral concentrate, liquid-related products	Moderate	Taste masking and liquid stability
Fluoxetine	Capsules, tablets, oral solution	Moderate	Liquid dosing and long half-life positioning
Escitalopram	Tablets and oral solution	Low to moderate	Low-dose uniformity and liquid delivery
Venlafaxine	Immediate- and extended-release products	High for extended release	Multiparticulate and release-control systems

Paroxetine has a stronger formulation-development rationale than many simple immediate-release SSRIs because controlled-release and low-dose products are commercially established. Its disadvantage is a mature, price-sensitive market and limited opportunity for premium pricing without a clinically meaningful delivery improvement.

What manufacturing and intellectual-property barriers matter most?

The main barriers are process robustness and regulatory equivalence rather than raw-material scarcity.

Critical manufacturing controls include:

• Active-ingredient particle-size distribution
• Blend uniformity at low dose
• Lubrication time
• Compression force
• Tablet porosity
• Polymer viscosity and hydration
• Coating weight gain
• Residual moisture
• Dissolution across pH conditions
• Capsule-fill weight variation
• Packaging moisture ingress

The most defensible commercial programs combine a differentiated formulation with a scalable process. A formulation that requires narrow polymer specifications, specialized coating equipment, or extensive manual testing may lose its margin advantage.

What is the commercial outlook for paroxetine excipient products?

The commercial outlook is segmented.

Opportunity	Market attractiveness	Technical risk	Likely pricing power
Conventional immediate-release tablet	High volume	Low	Low
Controlled-release generic	Moderate volume	High	Moderate
7.5 mg menopause product	Moderate	Moderate	Moderate
Pediatric or geriatric liquid	Niche	Moderate to high	Moderate
Orally disintegrating tablet	Niche	Moderate	Low to moderate
Specialty excipient platform	Depends on platform	High	High if broadly reusable

Revenue exposure is highest for manufacturers with high-volume immediate-release supply contracts. The most attractive strategic asset is a reusable controlled-release or taste-masking platform that can support multiple products beyond paroxetine.

Key Takeaways

• Immediate-release paroxetine is a mature, low-margin generic opportunity.
• Controlled-release paroxetine offers greater formulation and patent value but carries higher bioequivalence risk.
• Low-dose paroxetine mesylate creates opportunities in menopause-focused products and patient-friendly dosage forms.
• The most important excipient variables are content uniformity, release control, moisture protection, taste masking, and stability.
• Conventional excipient substitutions rarely create strong patent positions without a measurable technical effect.
• FDA Inactive Ingredient Database precedent and current Orange Book listings are central to regulatory and freedom-to-operate analysis.
• The strongest commercial model is a scalable excipient or manufacturing platform that can be applied across multiple controlled-release or low-dose products.

FAQs About Paroxetine Excipient Strategy

Can paroxetine be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating formulation is technically feasible, but taste masking, moisture protection, friability, and rapid disintegration must be controlled. Bioequivalence and exposure should be assessed against the relevant reference product.

Which excipient is most important for controlled-release paroxetine?

The release-controlling polymer system is usually the most important. Hypromellose, polyethylene oxide, ethylcellulose, and coating polymers can materially affect hydration, diffusion, erosion, and dissolution.

Is paroxetine suitable for a pediatric liquid formulation?

It can be developed as a liquid or suspension where the indication and regulatory pathway support the product. Taste masking, preservative effectiveness, dose accuracy, and stability are the main development issues.

Does paroxetine have biologic or biosimilar competition?

No. Paroxetine is a small-molecule drug. Competition comes from generic tablets, capsules, liquids, and modified-release products rather than biosimilars.

What is the strongest patent strategy for a new paroxetine product?

The strongest strategy generally combines composition claims with process, release-profile, stability, and method-of-use claims. A routine excipient replacement has weaker patent prospects than a formulation that produces a documented improvement in dissolution, stability, tolerability, or dose uniformity.

References

1. U.S. Food and Drug Administration. (2013). Brisdelle (paroxetine) prescribing information.

2. U.S. Food and Drug Administration. (2018). Paxil CR (paroxetine hydrochloride) extended-release tablets prescribing information.

3. U.S. Food and Drug Administration. (2018). Paxil (paroxetine hydrochloride) tablets prescribing information.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development; ICH Q9: Quality risk management; ICH Q10: Pharmaceutical quality system.

6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.